BioBam-15

Research Overview

BAM15 (N5,N6-bis(2-fluorophenyl)-oxadiazolo[3,4-b]pyrazine-5,6-diamine) is a synthetic mitochondrial uncoupler first identified in 2014 through bioenergetic screening, with a growing body of preclinical research spanning metabolic, immunological, oncological, and neurological domains.^[1]

Mechanism of Action

BAM15 functions as a protonophore, directly increasing inner mitochondrial membrane permeability to protons. This dissipates the electrochemical gradient that drives ATP synthase, accelerating electron transport chain (ETC) activity and substrate oxidation.

A key distinction from classical uncouplers like DNP and FCCP: BAM15 selectively depolarizes the mitochondrial membrane without affecting plasma membrane potential. In vitro comparisons showed no caspase 3/7 activation by BAM15 up to 40 μM, while DNP and FCCP triggered caspase activity at 5 μM and 10 μM respectively.^[2]

AMPK Signaling

The drop in ATP caused by uncoupling activates AMP-activated protein kinase (AMPK) at threonine 172, triggering downstream metabolic programs. These include GLUT4 translocation for glucose uptake, ACC phosphorylation to accelerate fatty acid β-oxidation, and PGC-1α activation to support mitochondrial biogenesis.^[2]

AMPK also inhibits NF-κB nuclear translocation by blocking IκBα degradation, suppressing NLRP3 inflammasome priming. shRNA-mediated AMPK knockdown abolished these effects, confirming AMPK as a central downstream mediator.

Mitochondrial Quality Control

BAM15 initiates mitophagy via PINK1-ubiquitin and LC3II activation, selectively clearing damaged mitochondria. It also promotes expression of fusion protein Mfn2 while reducing fission proteins, shifting mitochondrial dynamics toward a more connected network.^[1]

Metabolic Research

In vitro studies in C2C12 myotubes showed enhanced mitochondrial respiratory kinetics and increased nutrient uptake following BAM15 exposure. Isotopic tracer studies confirmed increased glucose uptake and palmitate oxidation.

In diet-induced obese mouse models, BAM15 drove a shift toward fat oxidation and increased total energy expenditure, with whole-transcriptome sequencing identifying 937 differentially regulated transcripts — including pathways related to insulin signaling and AMPK/AKT/GLUT4 activation. Hepatic lipogenesis genes were markedly suppressed, with Srebf1 downregulated 490-fold and Scd1 898-fold in adipose tissue.^[2]

Hepatic Lipid Research

BAM15 exhibits high hepatic uptake via first-pass portal clearance, driving substrate oxidation and reducing lipid accumulation. In preclinical models, hepatic steatosis was reduced by approximately 75%, with trichrome staining confirming no fibrotic development.^[2]

A 2026 study found BAM15 demonstrated higher proton-uncoupling binding capacity than DNP and FCCP, while also promoting mitochondrial fusion, fission, autophagy, and TCA cycle activity in liver tissue.^[3]

Sepsis and Renal Research

In cecal ligation and puncture (CLP) sepsis models, BAM15 substantially improved 7-day survival and kidney function, with reductions in proximal tubule cell vacuolization across cortex and outer medulla regions.^[4]

BAM15 disrupts a key mtDNA damage feedback loop: by accelerating ETC electron transfer, it reduces mitochondrial superoxide production, decreasing mtDNA release — a potential companion biomarker for research monitoring. It also activates PGC-1α through AMPK and SIRT1, supporting mitochondrial biogenesis during sepsis models.

Cardiovascular Research

In western-diet-fed ApoE⁻/⁻ mouse models, BAM15 suppressed atherosclerotic plaque formation and reduced serum ALT, AST, and hepatic lipid levels. RNA-seq analysis identified IL1A, SRC, and CSF3 as key molecular targets, confirmed by molecular docking and western blot.^[5]

BAM15 also potently activates AMPK in vascular smooth muscle cells and inhibits artery constriction, suggesting relevance to vascular tone research. In endothelial cell models under hyperglycemic conditions, BAM15 reduced ROS and supported mitochondrial function.^[6]

Oncology Research

BAM15-induced mitochondrial depolarization restrains ATP-linked oxidative phosphorylation in cancer cell models, increasing superoxide and caspase-3/7 activity. Preclinical models include breast cancer, melanoma, AML, and non-small cell lung cancer, where it demonstrated concentration-dependent inhibition of proliferation and G2 cell cycle arrest.^[7]

In tumor immunology research, low-dose intratumoral BAM15 reshaped the tumor metabolome and enhanced CD8⁺ T cell tumor-killing activity. BAM15 also synergized with retinoic acid to drive neuroblastoma differentiation, triggering a metabolic shift from the pentose phosphate pathway to oxidative phosphorylation.^[8][9]

Neurodegeneration Research

In Caenorhabditis elegans, BAM15 reduced mechanosensory neuronal defects during aging and extended mean lifespan in both wild-type and ucp-4 mutant strains. Functional assays confirmed maintained touch responses and short-term associative memory in BAM15-treated aged nematodes.^[10]

In CLP sepsis mouse models, BAM15 attenuated sepsis encephalopathy by reducing mitochondrial damage and suppressing neuronal miR370-3p upregulation.

Signaling Pathway Summary

BAM15 is for research use only. 

References

1. Xiong G, Zhang K, Ma Y, Song Y, Zhang W, Qi T, et al. BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases. Frontiers Media SA; 2023. https://doi.org/10.3389/fendo.2023.1252141
2. Axelrod CL, King WT, Davuluri G, Noland RC, Hall J, Hull M, et al. BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control. Springer Science and Business Media LLC; 2020. https://doi.org/10.15252/emmm.202012088
3. Liu Z, Wang W, Wang S, Lv R, Li C, Sun C. Mitochondrial uncoupler BAM15 ameliorates liver lipid metabolism disorders by activating the AMPK pathway. Wiley; 2026. https://doi.org/10.1111/febs.70400
4. Tsuji N, Tsuji T, Yamashita T, Hayase N, Hu X, Yuen PST, et al. BAM15 treats mouse sepsis and kidney injury, linking mortality, mitochondrial DNA, tubule damage, and neutrophils. American Society for Clinical Investigation; 2023. https://doi.org/10.1172/jci152401
5. Ma M, Zhong J, Tai Y, Xu S, Pei Z, Wang X. Combining RNA-seq, molecular docking and experimental verification to explore the mechanism of BAM15 as a potential drug for atherosclerosis. Springer Science and Business Media LLC; 2025. https://doi.org/10.1038/s41598-025-98209-3
6. Tai Y, Li L, Peng X, Zhu J, Mao X, Qin N, et al. Mitochondrial uncoupler BAM15 inhibits artery constriction and potently activates AMPK in vascular smooth muscle cells. Elsevier BV; 2018. https://doi.org/10.1016/j.apsb.2018.07.010
7. Zhang M yin, Wang YN, Zhou YF, Wang SC, Mai SJ, Wang HY. Abstract 4687: Primary study on the anticancer role of BAM15 in lung cancer cells. American Association for Cancer Research (AACR); 2024. https://doi.org/10.1158/1538-7445.am2024-4687
8. Jiang X, Fan Z, Zhang Z, Zeng F, Sun T, Li Y, et al. Tumor metabolome remolded by low dose mitochondrial uncoupler elicites robust CD8+ T cell response. Springer Science and Business Media LLC; 2025. https://doi.org/10.1038/s41420-025-02584-9
9. Ye J, Jiang H, Tiche S, He C, Liu J, Bian F, et al. Restoring Mitochondrial Quantity and Quality to Reverse Warburg Effect and Drive Tumor Differentiation. Springer Science and Business Media LLC; 2024. https://doi.org/10.21203/rs.3.rs-5494402/v1
10. Cho I, Song HO, Ji HE, Yang S, Cho JH. BAM15 Relieves Neurodegeneration in Aged Caenorhabditis elegans and Extends Lifespan. MDPI AG; 2022. https://doi.org/10.3390/metabo12111129